Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies - Archive ouverte HAL Access content directly
Journal Articles Eurosurveillance Year : 2018

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Fichier principal
Vignette du fichier
eurosurv-23-9-1.pdf (533.4 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01976967 , version 1 (10-01-2019)

Identifiers

Cite

Marc Rondy, Esther Kissling, Hanne-Dorthe Emborg, Alin Gherasim, Richard Pebody, et al.. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance, 2018, 23 (9), ⟨10.2807/1560-7917.ES.2018.23.9.18-00086⟩. ⟨hal-01976967⟩
77 View
153 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More